Results 31 to 40 of about 25,722,272 (279)

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk [PDF]

open access: yesDiabetes Therapy, 2019
Patients with type 2 diabetes mellitus (T2DM) appear to have increased risk for fractures. In this context, the finding that canagliflozin, a sodium-glucose co-transporter-2 (SGLT) inhibitor, increased the risk for fracture compared with placebo in the Canagliflozin Cardiovascular Assessment Study (CANVAS), a large randomized controlled trial (RCT) in ...
Anastasia Erythropoulou-Kaltsidou   +2 more
openaire   +2 more sources

Sodium-glucose co-transporter-2 inhibitors and epicardial adiposity

open access: yesEuropean Journal of Pharmaceutical Sciences, 2023
Epicardial adipose tissue is a layer of adipocytes that physiologically surround the myocardium and play some physiologic roles in normal heart function. However, in pathologic conditions, the epicardial adipose tissue can present a potent cardiac risk factor that is capable of impairing heart function through several pathways, increasing the risk of ...
Habib Yaribeygi   +4 more
openaire   +2 more sources

Clinical response to sodium glucose co‐transporter 2 inhibitor ipragliflozin in a patient with metastatic renal cell carcinoma

open access: yesIJU Case Reports, 2019
Introduction Sodium glucose co‐transporter 2 inhibitors constitute a new class of antidiabetic medication. Sodium glucose co‐transporter 2 inhibitors have been shown to exert anticancer effects.
Keita Izumi   +4 more
doaj   +1 more source

SLC2A9 is a high-capacity urate transporter in humans [PDF]

open access: yes, 2008
Background Serum uric acid levels in humans are influenced by diet, cellular breakdown, and renal elimination, and correlate with blood pressure, metabolic syndrome, diabetes, gout, and cardiovascular disease. Recent genome-wide association scans have
Doblado M   +240 more
core   +1 more source

Emerging Role of Sodium–Glucose Co-Transporter 2 Inhibitors for the Treatment of Chronic Kidney Disease

open access: yesInternational Journal of Nephrology and Renovascular Disease, 2023
Rey Isidto,1 Romina Danguilan,2 Oscar Naidas,3 Russell Vilanueva,2 Mel-Hatra Arakama,2 Layla Marie Paraiso2 1HealthLink Medical, Surgical, Dental Clinics and Diagnostic Center, Iloilo City, Iloilo, Philippines; 2Department of Adult Nephrology, National ...
Isidto R   +5 more
doaj  

New possibilities of nephroprotection in patients with chronic heart failure in combination with chronic kidney disease and diabetes mellitus 2 or without it

open access: yesЛечащий Врач, 2022
Impaired kidney function has a negative impact on the course of heart failure in both patients with and without diabetes mellitus. Therefore, the development and study of the effectiveness of methods for the treatment of chronic heart failure, especially
E. V. Kovalenko   +2 more
doaj   +1 more source

The sodium-dependent D-glucose transport protein of Helicobacter pylori [PDF]

open access: yes, 2008
Helicobacter pylori is a gram-negative pathogenic microaerophile with a particular tropism for the mucosal surface of the gastric epithelium. Despite its obligatory microaerophilic character, it can metabolize D-glucose and/or D-galactose in both ...
Kim E. Bettaney   +21 more
core   +1 more source

Inhibitors of sodium-glucose transport protein 2: A new multidirectional therapeutic option for heart failure patients

open access: yesCardiology Journal, 2023
Several mechanisms have been suggested to explain positive cardiovascular effects observed in studies with sodium-glucose co-transporter 2 (SGLT2) inhibitors.
Jacek Kubica   +24 more
doaj   +1 more source

Impact of SGLT2 inhibitors treatment on the chronic kidney disease in people with type 2 diabetes

open access: yesJournal of Education, Health and Sport, 2022
Diabetes is the most common cause of CKD (chronic kidney disease). CKD is also one of the most important diabetic complication. SGLT2 (sodium glucose co‐transporter‐2) inhibitors are new class of medication used to lower high blood glucose level in ...
Marcin Czarkowski   +3 more
doaj   +1 more source

Effects of sodium glucose co-transporter 2 inhibitors on the kidney [PDF]

open access: yesDiabetes and Vascular Disease Research, 2018
Sodium–glucose cotransporter 2 inhibitors are antihyperglycaemic medications with an emerging evidence base for cardiovascular and kidney disease risk reduction. Sodium–glucose cotransporter 2 inhibitors medications lower plasma glucose by inhibiting glucose reabsorption in the proximal tubule of the kidney independent of insulin.
Natalia, de Albuquerque Rocha   +4 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy